ALCON's VEXOL OPHTHALMIC CORTICOSTEROID APPROVED DEC. 30 FOR TREATING POSTOP INFLAMMATION AND ANTERIOR UVEITIS; LAST 1994 NME RECEIVES PRIORITY REVIEW
• By The Pink Sheet
Alcon Labs' corticosteroid Vexol (rimexolone) was approved on Dec. 30 as the last new drug cleared by FDA during calendar year 1994. The 1% rimexolone suspension, designated "1P" (a new molecular entity given priority review), is indicated for treatment of post-operative inflammation following ocular surgery and treatment of anterior uveitis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.